promising in diagnosing disseminated candidiasis in cancer patients.
Systemic candidiasis is being encountered with increasing frequency in debilitated individuals such as cancer patients (3) . Moreover, the antemortem diagnosis of systemic candidiasis in the immunosuppressed patient is very difficult, often delaying institution of potentially effective therapy. Circulating fungal antigens, presumably of polysaccharidic nature, are believed to be present during Candida infections (1, 2, 7). Thus, a technique for detection of such antigens could be a valuable tool permitting the early diagnosis of this fungal infection.
The enzyme-linked immunosorbent assay (ELISA) has been recognized in recent years as a rapid, accurate, and specific method for the detection of antibodies and antigens in various infectious diseases (5) . A number of different microplate ELISA systems, including the indirect ELISA, the double-antibody-sandwich ELISA (6) , and a blocking assay ELISA (8), have been developed. We report herewith preliminary results from an investigation on an ELISA-inhibition microplate technique for the detection of Candida antigen in the sera of cancer patients.
The ELISA-inhibition technique used in the present study is similar in principle to that described by Yolken et al. (8) . A reaction mixture of a fixed amount of a rabbit anti-C. albicans antibody and the putative antigen-containing sample is transferred to microplates previously coated with C. albicans antigen. The unbound rabbit anti-C. albicans antibody of the reaction mixture binds to the antigen on the coated microplates, and this is detected by an enzyme labeled anti-rabbit antibody and assayed spectrophotometrically by color development. Inhibition or blocking of the color development as compared to the control indicates the presence of antigen in the test sample. Since human sera may contain anti-Candida antibodies that could result in false negatives, all the sera were pretreated with NaOH (1 volume of 3 N NaOH to 5 volumes of serum; final NaOH concentration, 0.5 N) at 56°C for 2 h, followed by dialysis against phosphate-buffered saline (PBS; pH 7.4) for 24 h. Polyvinyl microplates (Cooke Laboratories, Alexandria, Va.) were coated with C. albicans mannan. Mannan was prepared from serotype A C. albicans, Hasenclever strain B 311, by the method of Peat (4). On Kjeldahl assay, the mannan contained 0.55% nitrogen by weight. Coating of the microplates was performed by a procedure adapted from Voller et al. (6) ; namely, wells were filled by using a multichannel pipette (Titertek, Flow Laboratories, Rockville, Md.) with 100 ,il/well of mannan (1,000 ng/ml) made up in a carbonate buffer (pH 9.6) and incubated overnight at 4°C. Before placement in the antigen-coated wells, the NaOH-treated and dialyzed sera were preincubated with whole rabbit anti-Candida serum which had been raised by intravenous injection of rabbits with C. albicans cells. The preincubation was performed in polystyrene microplates (Linbro Scientific Co., Hamden, Conn.), using PBS-0.05% Tween 20 as diluent (100 ,il of sample and 5 ,ul of rabbit antibody in a previously determined concentration per well), and incubated at 4°C overnight. (Tables 1 and 2 ). Group I (Table 1) consisted of randomly chosen paired sera (collected at least 2 weeks apart) from 10 patients. None of the patients were considered clinically to have systemic candidiasis. Routine surveillance cultures of nose, throat, and either stool or rectum within 1 week of the serum sample revealed C. albicans in 7 of 10 patients, but none of the patients in this group had evidence of systemic candidiasis. The inhibition of the group I sera ranged from no inhibition or even higher optical density values as compared to control, to 12% inhibition (e.g., 12% lower optical density values than the control) ( Table 1) . A second group of 17 patients ( Table 2 ) was chosen and studied blindly. Seven had autopsy-documented systemic candidiasis, whereas the remaining 10 patients had no evidence of systemic candidiasis demonstrable on postmortem examination. In the group II sera (Table 2) , four sera of the seven from patients with proven candidiasis had an inhibition of 40 to 56%, and the three other sera had an inhibition of 20 to 39%. Inhibition of the remaining 10 sera from patients without candidiasis ranged from negative to 17%. The inhibition percentages of the sera from the patients with autopsy-proven candidiasis could corre- 
